Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2E3 | Q9Y5X4 | 7/20 | 0.61 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | MMP9 | P14780 | 4/20 | 0.50 |
| ▸ | MMP8 | P22894 | 4/20 | 0.50 |
| ▸ | MMP13 | P45452 | 4/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136390 | 0.96 | NR2E3 (0.59) | NR2E3MMP2MMP9MMP8MMP13 | |
| SCHEMBL1136351 | 0.94 | NR2E3 (0.55) | NR2E3MMP2MMP9MMP8MMP13 | |
| SCHEMBL4487422 | 0.88 | MMP2 (0.58) | NR2E3MMP2MMP9MMP8MMP13 | |
| SCHEMBL1136378 | 0.88 | MMP2 (0.53) | NR2E3MMP2MMP9MMP8MMP13 | |
| SCHEMBL4472721 | 0.87 | NR2E3 (0.59) | NR2E3KDR | |
| SCHEMBL1136446 | 0.87 | KMT2A (0.50) | NR2E3MAPTMEN1LMNAKMT2A | |
| SCHEMBL1136458 | 0.87 | CHEK2 (0.52) | NR2E3MAPTKDM4ESMN1; SMN2KDR | |
| SCHEMBL1136430 | 0.87 | NR2E3 (0.47) | NR2E3MAPTKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1136391 | 0.86 | NR2E3 (0.46) | NR2E3MMP2MMP9MMP13MAPT | |
| SCHEMBL1136392 | 0.86 | NR2E3 (0.46) | NR2E3MMP2MMP9MMP13MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| CN-101208338-B | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE | 2010-12-29 | — | — | CN | claimed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | claimed |
| CN-101208338-A | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | claimed |
| EP-1919910-B1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | disclosed |
| CN-101208338-B | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE | 2010-12-29 | — | — | CN | disclosed |
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-10 | — | — | US | disclosed |
| CN-101208338-A | Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents | HOFFMANN LA ROCHE (CH) | 2008-06-25 | — | — | CN | disclosed |
| EP-1919910-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. Hoffmann-la Roche AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007017143-A1 | AZABENZIMIDAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227578-A1 | Azabenzimidazole Derivatives, Their Manufacture and Use as Anti-Cancer Agents | AZI2, CDKN1A, CCNI | NR2E3 2691/4885MMP2 1903/4885MMP9 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.